Home > Healthcare > Pharmaceuticals > Finished Drug Form > Peptide Therapeutics Market

Peptide Therapeutics Market - By Type (Branded, Generic), Application (Metabolic, Cancer, Cardiovascular, Gastrointestinal), Route of Administration (Parenteral, Oral), Distribution Channel (Hospital, Retail)- Global Forecast 2023-2032

  • Report ID: GMI5635
  • Published Date: May 2023
  • Report Format: PDF

Peptide Therapeutics Market Size

Peptide Therapeutics Market was evaluated to be around USD 39.3 billion in 2022 and is projected to witness massive growth at a CAGR of around 7.5% from 2023 to 2032. The rising prevalence of chronic diseases such as diabetes, obesity, and cancer has increased the demand for more effective and tailored treatments.

Peptide Therapeutics Market

For instance, according to National Diabetes Statistics Report for 2022, diabetes affected 37.3 million individuals, or 11.3% of the population in the U.S. and it has been diagnosed in an estimated 28.7 million people in 2019. In addition, according to Centers for Disease Control and Prevention (CDC), over 37 million Americans have diabetes, with around 90-95% of them having type 2 diabetes. Type 2 diabetes is most common in people over the age of 45, although it is also growing more prevalent in children, teenagers, and young adults.

Peptides consist of short chains of amino acids connected by peptide bonds. Peptide therapeutics serve as crucial replacement therapies that supplement peptide hormones when there are insufficient endogenous levels. Peptides bind to specific surface receptors and their ligands on cells, thus aiding in the treatment of diseases by influencing the cell membrane.


COVID-19 Impact

The COVID-19 has moderately impacted the growth of the peptide therapeutics market worldwide. Due to the therapeutic effect of peptide drugs, the key players in this market started developing peptide-based therapeutics for treating COVID-19. Due to this, many of the peptide-based vaccines for the treatment of COVID-19 was in clinical trials. The continuous support and investments of the government in the research and development of peptide therapeutics will help expand this market. For the treatment of acute respiratory distress syndrome (ARDS) and associated respiratory problems brought on by the SARS-CO-2 infection, about 21 peptide drugs, among which 15 are synthetic peptide drugs, were in development.

Peptide Therapeutics Market Trends

  • Researchers have been focusing on developing novel and effective peptide therapies for various diseases, including cancer, given the advantages of peptide therapeutics, such as their ease of synthesis, high target specificity, selectivity, and low toxicity. Peptide therapeutics are considered a promising and effective treatment option for cancer patients due to these advantages over chemotherapy and radiation therapy.
  • Additionally, R&D investment includes the development of novel medication delivery systems for peptides. This enables the creation of sustained-release formulations, controlled release, and targeted delivery to specific tissues or cells, enhancing the therapeutic potential of peptides.
  • Furthermore, technological improvements have enabled the creation of extensive peptide libraries with diverse sequences. High-throughput screening technologies and next-generation sequencing allow researchers to explore a wide range of peptide candidates for drug development efficiently.

These trends collectively shape the landscape of peptide therapeutics, driving innovation, expanding applications, and enhancing the potential for personalized medicines and targeted treatment options in various disease areas.

Peptide Therapeutics Market Analysis

Peptide Therapeutics Market Size, By Type, 2021 - 2032 (USD Billion)

Based on type, the market is subdivided into branded and generic peptide. Branded peptide segment accounted for a dominant segmental share in 2022 and is anticipated to expand at 7.7% CAGR from 2023 to 2032.

  • Branded peptides are protected by strong patents, ensuring exclusivity and restrict other firms from making and selling the identical peptide for a certain length of time. This exclusivity allows firms to recoup their R&D investments while maintaining a competitive edge.
  • Generic peptide segment is set to witness considerable growth and reach USD 27.1 billion by 2032. After the patent monopoly of the pioneer peptide expires, generic peptides become accessible. This term, known as market exclusivity, permits generic manufacturers to enter the market and provide more cost alternative. It ensures that patients retain access to critical therapies.

Based on applications, the peptide therapeutics market is classified into metabolic disorders, cancer, cardiovascular, gastrointestinal, central nervous system, infectious diseases, respiratory disorders, pain management, renal disorders, dermatology, and other applications. The metabolic disorders segment accounted for the largest share of 35.4% in 2022 due to the high prevalence of metabolic diseases such as diabetes.

  • According to a National Centre for Biotechnology Information (NCBI) article published in 2023, it is estimated that metabolic syndrome (MetS) affects 20-30% of the adult population globally, creating significant health, social, and economic consequences.
  • Moreover, natural hormones involved in metabolism, such as insulin, GLP-1 receptor agonist, and leptin, can be replicated or modulated by peptides. Peptide therapies can help restore normal metabolic function by modulating these biological processes, contributing to the segment progress.

Based on route of administration the peptide therapeutics market is subdivided parenteral, oral, and other routes of administration. The parenteral segment accounted for USD 31.6 billion in 2022 and is expected to witness the highest growth at 7.6% CAGR from 2023 to 2032.

  • Parenteral administration allows for precise and accurate dosage. This is particularly crucial when providing vital or strong peptide medications since it reduces the possibility of underdosing or overdose.
  • In addition, peptide medicines delivered parenterally often have better bioavailability than those supplied orally. By avoiding the gastrointestinal tract, the medicine is less likely to be degraded by digestive enzymes and can enter systemic circulation more quickly.

 Peptide Therapeutics Market Share, By Manufacturer Type (2022)

Based on manufacturer type, the peptide therapeutics market is classified into in-house and outsourced. The in-house segment dominated the market with the highest market share of around 64.7% in 2022 and is expected to grow at the highest CAGR during the forecast period.

  • In-house development enables companies to retain complete control over their intellectual property, such as unique peptide sequences, medication delivery technology, and formulation procedures. This level of management is critical for protecting investments and fostering innovation.
  • Moreover, companies may acquire more ownership over the costs involved with in-house development. They can monitor spending for R&D, manufacturing, and quality control, enabling for more effective budget management.

Based on synthesis technology, the peptide therapeutics market is subdivided into liquid-phase peptide synthesis, solid-phase peptide synthesis, and hybrid technology. The liquid-phase peptide synthesis (LPPS) segment held the majority of market share in 2022 and is expected to reach USD 41 billion by 2032.

  • LPPS is well-suited for native chemical ligation, a potent approach for forming a natural peptide connection with two synthetic peptide sections. This approach allows for the synthesis of larger and more complicated peptides and proteins, thus rendering it valuable in drugs development.
  • Also, due to the higher mobility of reactants in solution, LPPS frequently exhibits enhanced reaction kinetics. This has the potential to result in more rapid reaction times and more efficient peptide synthesis.

Based on distribution channel, the global peptide therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for USD 23.45 billion in 2022 and is expected to grow at 7.6% CAGR from 2023 to 2032.

  • They play an important role in the care and treatment of patients in a hospital setting. They guarantee that patients receive the appropriate drugs, including peptide-based treatments, at the appropriate timing and amount. In addition, peptide-based treatments frequently involve specific drugs with unique administration and storage requirements.
  • Additionally, hospitals are equipped to manage emergencies and rapidly and effectively dispense essential medications, including peptide-based pharmaceuticals, which is critical for patient care during emergencies.

U.S. Peptide Therapeutics Market, 2020- 2032 (USD Billion)

The North American peptide therapeutics market is expected to witness growth at 8.2% during the analysis period.

  • The North America high market revenue is owing to increasing prevalence of chronic disorders, rising healthcare expenditure, technological advancements, growing disposable income, etc. in the region. Moreover, rising incidences of metabolic disorders, cancer, cardiovascular disorders, gastrointestinal disorders, and central nervous system disorders are increasing the demand for effective peptide therapeutics for such conditions.
  • Additionally, North America, particularly the U.S. and Canada, has an advanced healthcare infrastructure that includes outstanding medical facilities, research institutes, and pharmaceutical companies. This infrastructure facilitates peptide-based treatment research, development, production, and delivery.

Peptide Therapeutics Market Share

The global market is dominated by some of the major market players. Few of the players operating in the market include Pfizer, Inc, Amgen, Inc, Eli Lilly and Company, AstraZeneca Plc, among others. The major market players in the market implement several strategies to maintain a competitive edge in the market. These players are engaged in partnerships, expansions, product launches, strategic acquisitions, mergers, and collaborations among other strategies.

Market players operating in the peptide therapeutics is as mentioned below:

  • Pfizer, Inc.
  • Amgen, Inc.
  • Eli Lilly and Company
  • Sanofi SA
  • AstraZeneca plc
  • AbbVie, Inc.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc
  • Sun Pharmaceutical Industries Ltd.
  • Novo Nordisk

Peptide Therapeutics Industry News:

  • In June 2018. Novo Nordisk and Kallyope Inc, announced to have entered into a research collaboration and option agreement to discover novel peptide therapeutics to treat obesity and diabetes. This strategy allowed to expand the business of peptide and thus increased the growth of the company.
  • In January 2018, Sun Pharmaceuticals Ltd., collaborated with the Washington University School of Medicine in St. Louis, and committed USD 10 million. This collaboration supported the development of small-molecule drugs based on hormones, peptides, and oligonucleotides for the treatment of common diseases. Thus, it helped the company to expand its product portfolio.

The peptide therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Billion from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

By Type, 2018 – 2032 (USD Billion)

  • Branded peptides
  • Generic peptides

By Application, 2018 – 2032 (USD Billion)

  • Metabolic & endocrine disorders
  • Cancer
  • Cardiovascular disorders
  • Gastrointestinal disorders
  • Central nervous system disorders
  • Respiratory disorders
  • Pain management
  • Renal disorders
  • Dermatology
  • Other applications

By Route of Administration, 2018 – 2032 (USD Billion)

  • Parenteral
  • Oral
  • Other routes of administration

By Manufacturer Type, 2018 – 2032 (USD Billion)

  • In-house
  • Outsourced

By Synthesis Technology, 2018 – 2032 (USD Billion)

  • Liquid phase peptide synthesis (LPPS)
  • Solid phase peptide synthesis (SPPS)
  • Hybrid technology

By Distribution Channel, 2018 – 2032 (USD Billion)

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Switzerland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of Middle East & Africa


Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Parenteral nutrition industry size was USD 5.7 billion in 2022 and is projected to record USD 11.2 million by 2032 due to the increasing prevalence of chronic diseases and gastrointestinal disorders across the world.

The RTU/standard commercial parenteral nutrition industry held 88.3% revenue share in 2022 and is projected to experience 7% CAGR from 2023-2032 driven by immense popularity among healthcare professionals for reducing the need for on-site compounding and ensuring accurate nutrient delivery.

North America garnered 30% of the parenteral nutrition industry share in 2022 and is anticipated to expand at 7.2% CAGR through 2023 owing to the presence of well-established healthcare infrastructure in the region.

B. Braun Melsungen AG, Baxter International, Inc., Fresenius Kabi AG, OTSUKA HOLDINGS CO., LTD, Amanta Healthcare, Grifols International S.A., ICU Medical, Aculife Healthcare, AbbVie, Inc, and Aguettant are some of the major parenteral nutrition industry players.

Peptide Therapeutics Market Scope

Buy Now

Immediate Delivery Available

Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 407
  • Countries covered: 21
  • Pages: 260
 Download Free Sample